HPV Antigens: Early vs. Late Proteins and Vaccine Targets

HPV Antigen Classification

HPV antigens are viral proteins expressed during the replication cycle. They are targets for immune recognition and vaccine design.

Early Antigens (E proteins)

• Expressed early in infection (basal/parabasal layers); regulate viral replication, cell cycle, immune evasion.
• E6, E7: Oncoproteins; degrade p53 and pRb → genomic instability, immortalization. Expressed in all HPV-associated cancers. Prime therapeutic vaccine targets.
• E1, E2: Viral replication/transcription; E2 represses E6/E7; lost in integration.
• E4, E5: Late early; viral release, growth factor modulation.

Late Antigens (L proteins)

• Expressed in differentiated superficial keratinocytes; structural.
• L1 (major capsid): Self-assembles into virus-like particles (VLPs). Basis of all prophylactic HPV vaccines (Gardasil 9, Cervarix). Induce high-titer neutralizing antibodies.
• L2 (minor capsid): Conserved across types; target for broad-spectrum next-gen vaccines.

Immune Response

• Natural infection: Weak, type-specific, mainly anti-L1; cell-mediated clearance (CD4⁺/CD8⁺) critical.
• Vaccination: Strong anti-L1 IgG → transudates to mucosa → prevents infection. >90% efficacy for covered types.
• Therapeutic vaccines (targeting E6/E7): In trials for CIN2/3 and HPV+ cancers.

Clinical Impact

Prophylactic vaccination (9–26 years, ideally pre-exposure) prevents cervical, anal, oropharyngeal, vaginal, vulvar, penile cancers and genital warts. Screening (Pap/HPV test) remains essential for unvaccinated/older populations.